Health Care/Hospital

HeyGears Announces One-Piece Denture Solution - Redefining Digital Dentures with Dual-Material 3D Printing

HeyGears' One-Piece Denture Solution enables dual-material denture DLP 3D printing, seamlessly fusing denture base and teeth materials in a single printing process to deliver more natural aesthetics and a comfortable fit. CHICAGO, Feb. 20, 2026 /PRNewswire/ -- HeyGears announces breakthrough One...

2026-02-20 22:00 1075

BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market

XI'AN, China, Feb. 19, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("Bon" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, today announced the successful development of a premium anti-aging facial mask incorpor...

2026-02-19 22:00 3702

Datasea Announces Foundational Research Breakthrough in Ultrasonic-Enhanced Nanoscale Precision Control

Establishing an Engineering-Level Core Technology for Next-Generation Semiconductor Manufacturing Applications BEIJING, Feb. 18, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology company specializing in acoustic high-tech solutions and 5G+AI ...

2026-02-18 22:30 3539

BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

XI'AN, China, Feb. 17, 2026 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-...

2026-02-17 22:00 4368

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...

2026-02-16 22:03 4176

CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)to initiate a Phase II clinical trial inpatients with advanced solid tumors. This marks a significant milestone in the global development of thi...

2026-02-16 08:10 3914

HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer

First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases,...

2026-02-13 14:04 3941

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...

2026-02-13 08:00 3442

SleepAI.com Introduces an AI-Powered Sleep and Emotional Wellness Platform for Modern Life

LOS ANGELES, Feb. 12, 2026 /PRNewswire/ -- SleepAI.com, a personalized AI sleep companion, today announced the launch of an AI-powered sleep and emotional wellness platform, now available on both the iOS and Google Play app stores. The platform is designed to address one of modern life's most per...

2026-02-13 02:00 3163

Datasea Reports Second Fiscal Quarter 2026 Results

Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalizati...

2026-02-12 22:20 9139

Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide

Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- On February 8, at the 2026 China New Drug Source Innovation Forum inShanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten...

2026-02-12 22:00 3459

Ubie Announces Collaboration to Reinvent the Healthcare Digital Front Door

* Ubie and Mayo Clinic collaborate with the goal of delivering a unified, AI-powered chat and voice platform to streamline healthcare access, reduce complexity and offer a best-in-class patient experience * Natural conversations, instant answers, and a seamless triage-to-booking flow will dri...

2026-02-12 22:00 3445

J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research

SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Associa...

2026-02-12 15:01 3248

WuXi Vaccines Receives Brazil's ANVISA GMP Certification

SUZHOU, China, Feb. 11, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish f...

2026-02-12 11:48 3475

Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications

HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139,  a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These i...

2026-02-11 17:01 4217

PharmaResearch Announces Supply Agreement for Rejuran in Brazil

SEONGNAM, South Korea, Feb. 11, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEOJihoon Sohn), a leading regenerative medicine company, announced that it has entered into an exclusive supply agreement for Rejuran with DermaDream, a Brazilian aesthetic company, as part of its preparations for ent...

2026-02-11 14:54 3388

On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully

SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. Th...

2026-02-10 21:07 3930

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceuti...

2026-02-10 21:00 4317

GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services

YONGIN, South Korea, Feb. 10, 2026 /PRNewswire/ -- GCCL Co., Ltd. (GCCL), a data-driven clinical trial services provider, and Medicover Integrated Clinical Services (MICS), part of Medicover, an international healthcare and diagnostic services company, have signed a Memorandum of Understanding (M...

2026-02-10 17:27 3813

WAT Medical's EmeTerm Wearable Device Demonstrates Superior Control of Moderate to Severe Postoperative Nausea and Vomiting in JAMA Surgery-Published Clinical Trial

VANCOUVER, BC, Feb. 9, 2026 /PRNewswire/ -- WAT Medical is proud to announce the publication of a landmark randomized clinical trial inJAMA Surgery, one of the world's most reputable and high-impact surgical journals. The study confirms that the EmeTerm wristband — a wearable device utilizing tr...

2026-02-10 03:08 4429
12345 ... 311

Week's Top Stories